Tag: richter

ING has on Tuesday raised its target price for Hungary’s Richter to HUF 30,000 from HUF 28,500 per share. As the new TP remains way below the current market price, ING has maintained its ‘Sell’... 

Hungary’s Richter has maintained its guidance for 2012 after releasing higher-than-expected profit figures for the first quarter on Thursday, thanks to milestones received by Watson and Forest. ... 

(Adds details, charts) The first-quarter profit of Richter, Hungary’s leading pharmaceutical producer, came in greatly above market consensus, the company’s Q1 earnings report showed on Thursday.... 

Hungarian drug producers Egis and Richter are expected to report smaller profits for the first quarter of 2012 than their respective Q1 2011 numbers, the consensus estimates of analysts showed in a Portfolio.hu... 

Deutsche Bank has revised its valuation model for Richter and slashed its target price for the Hungarian drugs producer to HUF 40,000 from HUF 44,000 previously. However, it maintained its ‘Hold’... 

Hungary’s drug prices to be in effect from 1 April have become final last week with a ‘blind bidding’ by producers. Both Richter and Egis had to carry out massive price reductions at... 

U.S. Forest Laboratories and Hungary’s Gedeon Richter Plc. Announced on Tuesday morning positive topline results in two Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute... 

Richter, Hungary’s leading drugs producer has on Tuesday announced what the investor community has been waiting for months or even years: the results from two positive Phase III Trials with the investigational... 

(Adds company comment) Gedeon Richter Plc., Hungary’s leading pharmaceutical producer, has announced on Monday that the European Commission has granted marketing authorization to Esmya 5mg tablet... 

Gedeon Richter Plc., Hungary’s largest drugs producer, has announced on Friday that as a result of disposal of shares by the Pension Reform and Debt Reduction Fund’s (Nyugdíjreform és Adósságcsökkentő... 

Hungary’s Gedeon Richter and U.S.-based Forest Laboratories, Inc. have announced on Wednesday preliminary top-line results from a Phase III clinical trial of cariprazine (RGH-188), an investigational... 

Hungary’s Richter Gedeon has exceeded the EUR 1 billion revenue mark thanks to the acquisition of the oral contraceptive (OC) portfolio acquired from Grünenthal, CEO Erik Bogsch told a press conference... 

(Adds details, charts) Richter Gedeon, Hungary’s leading drugs producer, has reported almost double as large operating profit for the fourth quarter of 2011 than what analysts expected in a Portfolio.hu... 

Richter Gedeon, Hungary’s leading drugs producer is expected to publish its fourth-quarter 2011 earnings report this week. Analysts polled by Portfolio.hu project that the company will report a substantial... 

Erste has raised its target price for Richter, Hungary’s largest drugs producer, to HUF 45,650 per share from HUF 43,865 previously and reiterated its ‘Buy’ call. “With its fortunes... 

Gedeon Richter, Hungary’s largest drugs maker, and HRA Pharma have announced on Monday that they have entered into a licensing agreement, under the terms of which Richter received the exclusive distribution... 

Watson Pharmaceuticals has announced that it has received FDA approval for Vestura, its generic version of Bayer’s Yaz® oral contraceptive product. This creates a rival for the drug of Hungary’s... 

Renaissance Capital of Russia has started coverage of Richter, Hungary’s leading drugs producer, with a HUF 36,697 target price and a ‘Hold’ rating. In a research note published on... 

Hungary’s leading drugs producer Richter continues to expect a 0-5% revenue increase in 2011, projecting its operating margin to reach 18%. The company will try to remain consistent in its dividend... 

ING has on Tuesday lowered its recommendation for Hungarian drugs producer Richter to ‘Sell’ from ‘Hold’. Richter released its Q3 preliminary earnings report today, which showed...